An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions
End Stage Renal Disease
Interventions
DEVICE

HemoCare™ Hemodialysis System

The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.

Trial Locations (7)

11021

The Rogosin Institute, New York

37203

Dialysis Clinic, Inc., Nashville

37920

Dialysis Clinic, Inc., Knoxville

39213

University of Mississippi Medical Center, Jackson

78744

Wellbound South Austin, Austin

78758

Wellbound North Austin, Austin

08902

DCI North Brunswick, North Brunswick

Sponsors
All Listed Sponsors
lead

Deka Research and Development

INDUSTRY